Department of Medical Intensive Care, University Hospital of Angers, 49100 Angers, France.
MITOVASC Laboratory, UMR INSERM (French National Institute of Health and Medical Research), 1083-CNRS 6015, University of Angers, 49933 Angers, France.
Int J Mol Sci. 2023 Feb 17;24(4):4103. doi: 10.3390/ijms24044103.
During hemorrhagic shock, blood loss causes a fall in blood pressure, decreases cardiac output, and, consequently, O transport. The current guidelines recommend the administration of vasopressors in addition to fluids to maintain arterial pressure when life-threatening hypotension occurs in order to prevent the risk of organ failure, especially acute kidney injury. However, different vasopressors exert variable effects on the kidney, depending on the nature and dose of the substance chosen as follows: Norepinephrine increases mean arterial pressure both via its α-1-mediated vasoconstriction leading to increased systemic vascular resistance and its β1-related increase in cardiac output. Vasopressin, through activation of V1-a receptors, induces vasoconstriction, thus increasing mean arterial pressure. In addition, these vasopressors have the following different effects on renal hemodynamics: Norepinephrine constricts both the afferent and efferent arterioles, whereas vasopressin exerts its vasoconstrictor properties mainly on the efferent arteriole. Therefore, this narrative review discusses the current knowledge of the renal hemodynamic effects of norepinephrine and vasopressin during hemorrhagic shock.
在失血性休克期间,失血会导致血压下降,心输出量减少,从而影响氧气输送。目前的指南建议,当发生危及生命的低血压时,除了输液外,还应使用血管加压药来维持动脉压,以预防器官衰竭(特别是急性肾损伤)的风险。然而,不同的血管加压药对肾脏的作用不同,这取决于所选择的物质的性质和剂量,具体如下:去甲肾上腺素通过其介导的α-1 血管收缩增加全身血管阻力,同时通过β1 相关的增加心输出量来增加平均动脉压。血管加压素通过激活 V1-a 受体诱导血管收缩,从而增加平均动脉压。此外,这些血管加压药对肾血流动力学有以下不同的影响:去甲肾上腺素收缩入球小动脉和出球小动脉,而血管加压素主要在出球小动脉发挥其血管收缩作用。因此,本综述讨论了目前关于去甲肾上腺素和血管加压素在失血性休克期间对肾血流动力学影响的知识。